124 related articles for article (PubMed ID: 10644041)
21. Increased sensitivity to cisplatin in gastric cancer by antisense inhibition of the her-2/neu (c-erbB-2) gene.
Funato T; Kozawa K; Fujimaki S; Miura T; Kaku M
Chemotherapy; 2001; 47(4):297-303. PubMed ID: 11399867
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
[TBL] [Abstract][Full Text] [Related]
23. Anti-apoptotic effects of protein kinase C-delta and c-fos in cisplatin-treated thyroid cells.
Muscella A; Urso L; Calabriso N; Vetrugno C; Rochira A; Storelli C; Marsigliante S
Br J Pharmacol; 2009 Mar; 156(5):751-63. PubMed ID: 19254279
[TBL] [Abstract][Full Text] [Related]
24. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis.
Yamamoto K; Okamoto A; Isonishi S; Ochiai K; Ohtake Y
Biochem Biophys Res Commun; 2001 Feb; 280(4):1148-54. PubMed ID: 11162647
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
26. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
27. Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.
Parekh H; Simpkins H
Cancer Chemother Pharmacol; 1996; 37(5):457-62. PubMed ID: 8599869
[TBL] [Abstract][Full Text] [Related]
28. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
29. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells.
Hirama M; Isonishi S; Yasuda M; Ishikawa H
Oncol Rep; 2006 Nov; 16(5):997-1002. PubMed ID: 17016583
[TBL] [Abstract][Full Text] [Related]
30. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
32. The utility of an anti-fos ribozyme in reversing cisplatin resistance in human carcinomas.
Funato T; Yoshida E; Jiao L; Tone T; Kashani-Sabet M; Scanlon KJ
Adv Enzyme Regul; 1992; 32():195-209. PubMed ID: 1496917
[TBL] [Abstract][Full Text] [Related]
33. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
34. On the role of c-fos expression in striatal transmission. The antisense oligonucleotide approach.
Sommer W; Fuxe K
Neurochem Int; 1997 Sep; 31(3):425-36. PubMed ID: 9246684
[TBL] [Abstract][Full Text] [Related]
35. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
36. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
37. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
38. c-fos is a positive regulator of carcinogen enhancement of adenovirus transformation.
Su ZZ; Yemul S; Stein CA; Fisher PB
Oncogene; 1995 May; 10(10):2037-49. PubMed ID: 7761104
[TBL] [Abstract][Full Text] [Related]
39. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of Hus1 by antisense oligonucleotides enhances the sensitivity of human lung carcinoma cells to cisplatin.
Kinzel B; Hall J; Natt F; Weiler J; Cohen D
Cancer; 2002 Mar; 94(6):1808-14. PubMed ID: 11920544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
